164 related articles for article (PubMed ID: 36864713)
21. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
22. Comparing the effectiveness of biosimilar filgrastim (Nivestim®) versus original filgrastim (Neupogen®) for stem cell mobilization in adult and pediatric healthy donors.
Muffarrej D; Hashem H; Tbakhi A; Najjar R
J Oncol Pharm Pract; 2023 Jun; ():10781552231171829. PubMed ID: 37357617
[TBL] [Abstract][Full Text] [Related]
23. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
[TBL] [Abstract][Full Text] [Related]
24. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
25. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.
Publicover A; Richardson DS; Davies A; Hill KS; Hurlock C; Hutchins D; Jenner MW; Johnson PW; Lamb J; Launders H; McKeag N; Newman J; Orchard KH
Br J Haematol; 2013 Jul; 162(1):107-11. PubMed ID: 23614650
[TBL] [Abstract][Full Text] [Related]
26. Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.
Maul JT; Stenner-Liewen F; Seifert B; Pfrommer S; Petrausch U; Kiessling MK; Schanz U; Nair G; Mischo A; Taverna C; Schmidt A; Bargetzi M; Stupp R; Renner C; Samaras P
J Clin Apher; 2017 Feb; 32(1):21-26. PubMed ID: 27001243
[TBL] [Abstract][Full Text] [Related]
27. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.
Sato K; Ishiyama K; Aoki G; Maruyama H; Tsuji N; Tanabe M; Zaimoku Y; Sato H; Yamazaki H; Yamaguchi M; Takami A; Nakao S
Int J Hematol; 2019 Dec; 110(6):648-653. PubMed ID: 31542851
[TBL] [Abstract][Full Text] [Related]
29. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.
Pham T; Patil S; Fleming S; Avery S; Walker P; Wei A; Curtis D; Stuart G; Klarica D; O'Brien M; Morris K; Das T; Bollard G; Muirhead J; Coutsouvelis J; Spencer A
Transfusion; 2015 Nov; 55(11):2709-13. PubMed ID: 26173921
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
Nasillo V; Paolini A; Riva G; Morselli M; Potenza L; Coluccio V; Maccaferri M; Colaci E; Fantuzzi V; Messerotti A; Arletti L; Pioli V; Lugli E; Gilioli A; Quadrelli C; Zucchini P; Vallerini D; Lagreca I; Barozzi P; Cuoghi A; Bresciani P; Marasca R; Mariano MT; Ceccherelli G; Comoli P; Campioli D; Trenti T; Narni F; Luppi M; Forghieri F
Leuk Lymphoma; 2018 Jan; 59(1):225-228. PubMed ID: 28587560
[No Abstract] [Full Text] [Related]
31. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
32. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
[TBL] [Abstract][Full Text] [Related]
33. Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis.
Parody R; Sánchez-Ortega I; Ferrá C; Guardia R; Talarn C; Encuentra M; Fort E; López D; Morgades M; Alonso E; Ortega S; Sarrá J; Gallardo D; Ribera JM; Sureda A
Oncol Ther; 2020 Dec; 8(2):311-324. PubMed ID: 32700041
[TBL] [Abstract][Full Text] [Related]
34. The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors.
Tsumanuma R; Omoto E; Kumagai H; Katayama Y; Iwato K; Aoki G; Sato Y; Tsutsumi Y; Tsukada N; Iino M; Atsuta Y; Kodera Y; Okamoto S; Yabe H
Int J Hematol; 2022 Jun; 115(6):882-889. PubMed ID: 35397766
[TBL] [Abstract][Full Text] [Related]
35. The role of biosimilar granulocyte colony stimulating factor (GCSF) Zarzio for progenitor cell mobilization and the treatment of therapy-induced neutropenia in adult hematopoietic stem cell transplantation.
Severson CC
Can Oncol Nurs J; 2015; 25(4):443-54. PubMed ID: 26897866
[TBL] [Abstract][Full Text] [Related]
36. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
37. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.
Becker P; Schwebig A; Brauninger S; Bialleck H; Luxembourg B; Schulz M; Tsamadou C; Wiesneth M; Reinhardt P; Mytilineos J; Seidl C; Gattu S; Kaliakina N; Singh P; Schrezenmeier H; Seifried E; Bonig H
Transfusion; 2016 Dec; 56(12):3055-3064. PubMed ID: 27633122
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.
Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Satake A; Ito T; Ishii K; Nomura S
J Blood Med; 2017; 8():5-12. PubMed ID: 28182150
[TBL] [Abstract][Full Text] [Related]
39. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.
Schmitt M; Xu X; Hilgendorf I; Schneider C; Borchert K; Gläser D; Freund M; Schmitt A
Bone Marrow Transplant; 2013 Jul; 48(7):922-5. PubMed ID: 23318540
[TBL] [Abstract][Full Text] [Related]
40. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.
Grigg AP; Roberts AW; Raunow H; Houghton S; Layton JE; Boyd AW; McGrath KM; Maher D
Blood; 1995 Dec; 86(12):4437-45. PubMed ID: 8541532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
